Journal
JOURNAL OF IMMUNOLOGY
Volume 182, Issue 9, Pages 5342-5351Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0801624
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Deutsche Forschungsgemeinschaft [Br1680/3-4]
Ask authors/readers for more resources
CD28(null) T cells are a highly enriched subset of proinflammatory T cells in patients with autoimmune diseases that are oligoclonal and autoreactive. In this study, we analyzed the role of CD152 signaling on the longevity of human CD28(null) T cells. Using a sensitive staining method for CD152, we show that human CD4(+)CD28(null) and CD8(+)CD28(null) T cells rapidly express surface CD152. Serological inactivation of CD152 using specific Fab or blockade of CD152 ligands using CTLA-4Ig in CD4(+)CD28(null) and CD8(+)CD28(null) T cells enhances apoptosis in a Fas/FasL-dependent manner., CD152 cross-linking on activated CD28(null) cells prevents activation-induced cell death as a result of reduced caspase activity. Apoptosis protection conferred by CD 152 is mediated by phosphatidylinositol 3'-kinase-dependent activation of the kinase Akt, resulting in enhanced phosphorylation and thereby inhibition of the proapoptotic molecule Bad. We show that signals triggered by CD152 act directly on activated CD28(null) T lymphocytes and, due to its exclusive expression as a receptor for CD80/CD86 on CD28(null) T cells, prevention of CD152-mediated signaling is likely a target mechanism taking place during therapy with CTLA-41g. Our data imply strongly that antagonistic approaches using CD152 signals for chronic immune responses might be beneficial. The Journal of Immunology, 2009, 182: 5342-5351.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available